Assessing and Monitoring Antipsychotic-Induced Movement Disorders in Hospitalized Patients: A Cautionary Study

Canadian Journal of Psychiatry

Volumn 49, Issue 1, 2004, Pages 31-36

  Cortese, Leonardo ^a,b   Jog, Mandar ^b   McAuley, T Jeffrey ^b,c,d   Kotteda, V ^e   Costa, Giuseppe ^f  

^a WINDSOR REGIONAL HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Department of Psychiatry   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f WESTERN UNIVERSITY   (Canada)

Author keywords

Akathisia; Assessment; Documentation; Dystonia; Extrapyramidal side effects; Extrapyramidal symptoms; Parkinsonism; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; AKATHISIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MONITORING; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; PARKINSONISM; PHYSICAL EXAMINATION; TARDIVE DYSKINESIA;

EID: 0842343519     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900105     Document Type: Article

References (46)

1. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993;16:589-609.
2. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV, editors. Psychopharmacology: current trends. Berlin: Springer-Verlag; 1988. p 74-93.
3. Sovner R, DiMascio A. Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA, Dimascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven Press; 1978. p 1021-32.
4. Kane JM, Woemer M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988;8(Suppl 4):52-6.
5. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Apr Suppl):1-63.
6. Kane J, Honigfeld G, Singer J, and others. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
7. Chouinard G, Jones B, Remington C, and others. A Canadian multi-centre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
8. Tollefson D, Bensley CM J, Tran PV, and others. Olanzapine versus haloperidol in the treatment of schizophrenia and schizo-affective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
9. Borison RL, Arvanitis LA, Miller BG. ICI 204,636. An atypical antipsychotic: efficacy and safety in a multi-centre, placebo controlled trial in patients with schizophrenia. US Seroquel Study Group. J Clin Psychopharmacol 1996;16:158-69.
10. Meltzar HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999;60(Suppl 3):3-7.
11. Awad AG, Voruganti LN: Quality of life and new antipsychotics in schizophrenia: are patients better off? Int J Soc Psychiatry 1999;45:268-75.
12. 2 occupancy, clinical responses, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20.
13. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
14. Tran PV, Hamilton SH, Kuntz AJ, and others. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
15. Cortese L, and others. Extrapyramidal symptoms in drug-naive patients with schizophrenia. Abstract presented at the International Congress on Schizophrenia Research; April 2001; Whistler (BC).
16. Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand 1996;94:12-7.
17. Caligiuri MP, Lohr JB, Jeste DV. Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 1993;150:1343-8.
18. Chatterjee A, Chakos M, Koreen A, and others. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-9.
19. Drake RE, Erlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142:499-501.
20. Weiden P, Shaw E, Mann JJ. Causes of neuroleptic non compliance. Psychiatr Ann 1986;16:571-85.
21. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-45.
22. Weiden PJ, Mann J, Haas G, Mattson M, Francis A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987;139:372-3.
23. Hansen TE, Brown WL, Weigel RM, Casey DE. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry 1992;14:340-4.
24. Rigby JC, Oswald AG. An evaluation of the performing and recording of physical examinations by psychiatric trainees. Br J Psychiatry 1986;150:533-5.
25. Task Force on Late Neurological Effects of Antipsychotic Drugs. Tardive dyskinesia: summary of a task force report. Am J Psychiatry 1980;137:1163-72.
26. Tardive dyskinesia: a task force report. Washington (DC): American Psychiatric Association; 1992.
27. Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(Suppl 2 Revised).
28. Benjamin S, Munetz MR. CMHC Practices related to tardive dyskinesia screening and informed consent for neuroleptic drugs. Hosp Community Psychiatry 1994;45:343-6.
29. Schachter D, Keinman I. Psychiatrists' documentation of informed consent. Can J Psychiatry 1998;43:1012-7.
30. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association to tardive dyskinesia. J Clin Psychopharmacol 1999;19:203-8.
31. Wichmann T, Delung MR. Hypokinetic movement disorders. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 1997. p 90-1.
32. Tsai CH, Lu CS. Early onset parkinsonism in Chinese. J Formos Med Assoc 1991;90:964-9.
33. Cem Atbasoglu E, Schultz SK, Andreasen NC. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001;13:336-41.
34. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-35.
35. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987;480160-6689:13-9.
36. Siris SG. Three cases of akathisia and "acting out." J Clin Psychiatry 1985;46:395-7.
37. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142:499-501.
38. Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 1983;3:235-6.
39. Van Putten T. Vulnerability to extrapyramidal side effects. Clin Neuropharmacol 1983;60362-5664:527-34.
40. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000;6161:10-4.
41. Puri BK, Barnes TR, Chapman MJ, Hutton SB, Joyce EM. Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry 1999;66(1):76-8.
42. Gervin M, and others. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 1998;155:1202-6.
43. Chatterjee A, and others. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-9.
44. Mossman D, Lehrer D. Conventional and atypical antipsychotics and the evolving standard of care. Psychiatr Serv 2000;51:1528-35.
45. Katzung BG. Adverse effects of muscarinic receptor-blocking drugs. In: Katzung BG, editor. Basic and clinical pharmacology. 7th ed. Stamford (CT): Appleton and Lange; 1998. p 113-4.
46. Dixon L, Weiden PJ, Frances AJ, Rupkin B. Management of neuroleptic-induced movement disorders: effects of physician training. Am J Psychiatry 1989;146:1:104-6.